ChromaDex Corporation Reports 2020 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) announced its fourth quarter and full-year 2020 financial results, reporting total net sales of $15.4 million for Q4, an 18% increase from the previous year. Tru Niagen® sales reached $12.3 million, up 21%. The company improved its gross margin to 61.0% and reduced its net loss to ($6.1 million), resulting in a loss per share of ($0.10). Full-year net sales were $59.3 million, a 28% increase, with a net loss of ($19.9 million). The company expects continued revenue growth and margin improvement in 2021.
- Net sales increased by 28% to $59.3 million in FY 2020.
- Tru Niagen® net sales up 31% to $47.1 million in FY 2020.
- Gross margin improved by 390 basis points to 59.5% for FY 2020.
- Adjusted EBITDA loss improved by $7.8 million year-over-year.
- Reported a net loss of ($19.9 million) or ($0.33) per share for FY 2020.
- Increased selling and marketing expenses as a percentage of net sales.
ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter and full year 2020 financial results.
Fourth Quarter 2020 and Recent Highlights
-
Total net sales of
$15.4 million , up18% from$13.1 million in the year ago quarter. -
Tru Niagen® net sales of
$12.3 million , a21% increase from the year ago quarter. -
Gross margin of
61.0% , a 400 basis point increase from the year ago quarter. -
Net loss was (
$6.1) million or ($0.10) per share, an improvement of$0.05 per share year-over-year. -
Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of (
$1.1) million , a$1.0 million improvement year-over-year. - Growing body of clinical research suggests that nicotinamide riboside (“NR”) may support important areas of human health.
- Phase 2 clinical study showed a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol that included NR.
- Phase 3 clinical study on 300 patients in Turkey with mild-to-moderate COVID-19 showed a 3.5 day reduction in recovery time when adding a daily nutritional protocol that included NR to the local standard of care.
- Tru Niagen® received the ‘Most Favourite Brand’ award by Watsons Hong Kong loyalty members for the second consecutive year.
Full Year 2020 Highlights
- Delivered on financial outlook to investors across all metrics. Slightly better than target on selling and marketing and G&A expense.
-
Total net sales of
$59.3 million , up28% from$46.3 million in the prior year. -
Tru Niagen® net sales of
$47.1 million , a31% increase from$36.1 million in the prior year. -
Gross margins of
59.5% , a 390 basis point increase from the prior year. -
Lower selling and marketing expense as a percentage of net sales (
35.4% in 2020 versus39.4% in 2019). -
Net loss was (
$19.9) million or ($0.33) per share, an improvement of$0.24 per share year-over-year. -
Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of (
$1.0) million for FY 2020, a$7.8 million improvement year-over-year. - Signed 225th material transfer agreement through ChromaDex External Research Program (CERP), which has resulted in 60 published studies to date, including 11 published clinical studies, on Niagen®.
- Expanded in Europe and Australia, following regulatory approval for Tru Niagen®.
- Nestlé Health Science’s new Celltrient™ Cellular Energy products featuring Tru Niagen® launched in the United States, following the launch of Tru Niagen® capsules on Persona, a Nestlé Health Science company and leading personalized vitamin subscription program, earlier this year.
- ChromaDex Chief Scientific Advisor, Dr. Charles Brenner, Receives 2020 National Scientific Achievement Award from the American Society for Nutrition.
“ChromaDex’s philosophy of focusing on business fundamentals with a science-based strategic approach continued in 2020,” said ChromaDex CEO Rob Fried. “In 2021, we will further our position as the world's leading NAD+ company by growing the Tru Niagen® brand, extending partnerships and furthering scientific advancements with world-leading scientists."
Results of operations for the three months ended December 31, 2020
For the three months ended December 31, 2020 (“Q4 2020”), ChromaDex reported net sales of
Gross margin percentage improved by 400 basis points to
Operating expenses decreased by
The net loss for Q4 2020 was (
Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of (
ChromaDex defines Adjusted EBITDA excluding total legal expense as net income or (loss) which is adjusted for interest, income tax, depreciation, amortization, non-cash stock compensation costs, severance and restructuring expense, bad debt expense related to Elysium Health and total legal expense.
For Q4 2020, the net cash flow from operating activities was at break-even, versus (
Results of operations for the year ended December 31, 2020
For the full year ended December 31, 2020 (“FY 2020”), ChromaDex reported net sales of
Gross margin percentage improved by 390 basis points to
Operating expenses decreased by
The net loss for FY 2020 was (
Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of (
For full year 2020, the net cash used in operating activities was (
2021 Outlook
Looking forward, the Company expects continued, steady revenue growth driven by its global ecommerce business, as well as growth with existing and new strategic partners. The Company expects continued gross margin improvement to slightly better than
Investor Conference Call
ChromaDex management will host an investor conference call to discuss the fourth quarter results and provide a general business update on Wednesday, March 10, at 4:30pm ET.
Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
Date: Wed., March 10, 2021
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll-free dial-in number: 1-833-979-2703
International dial-in number: 236-714-2223
Conference ID: 8433848
Webcast link: ChromaDex Fourth Quarter 2020 Earnings Conference Call
The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.
A replay of the conference call will be available after 7:30 p.m. ET.
Toll-free replay number: (800) 585-8367
Replay ID: 8433848
The earnings press release, and its accompanying financial exhibits, will be available on the Investor Relations section of the Company website, www.chromadex.com.
About Non-GAAP Financial Measures:
Adjusted EBITDA excluding total legal expense excludes interest, income tax, depreciation, amortization, non-cash share-based compensation costs, severance and restructuring expense, bad debt expense related to Elysium Health, and total legal expense. ChromaDex used these non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. ChromaDex believes the presentation of its non-GAAP financial measures enhances the overall understanding of the company’s historical financial performance. These non-GAAP measures should not be viewed in isolation from or as a substitute for ChromaDex’s financial results in accordance with GAAP. Reconciliation of GAAP to non-GAAP measures are attached to this press release.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), which is protected by ChromaDex’s patent portfolio along with other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Important Note on Forward Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include the quotation from ChromaDex’s Chief Executive Officer, and statements related to the company’s 2021 financial outlook, including the impact of COVID-19. Other risks that contribute to the uncertain nature of the forward-looking statements are reported in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
| ChromaDex Corporation and Subsidiaries | |||||||
| Consolidated Statements of Operations | |||||||
| Three Months Ended December 31, 2020 and December 31, 2019 | |||||||
| (In thousands, except per share data) | |||||||
| Three Months Ended | |||||||
| Dec. 31, 2020 | Dec. 31, 2019 | ||||||
| Sales, net | $ |
15,445 |
|
$ |
13,089 |
|
|
| Cost of sales |
|
6,024 |
|
|
5,624 |
|
|
| Gross profit |
|
9,421 |
|
|
7,465 |
|
|
| Operating expenses: | |||||||
| Sales and marketing |
|
6,319 |
|
|
5,108 |
|
|
| Research and development |
|
991 |
|
|
1,139 |
|
|
| General and administrative |
|
8,192 |
|
|
10,078 |
|
|
| Operating expenses |
|
15,502 |
|
|
16,325 |
|
|
| Operating loss |
|
(6,081 |
) |
|
(8,860 |
) |
|
| Nonoperating income (expense): | |||||||
| Interest income (expense), net |
|
(16 |
) |
|
7 |
|
|
| Nonoperating income (expense): |
|
(16 |
) |
|
7 |
|
|
| Net loss |
|
(6,097 |
) |
|
(8,853 |
) |
|
| Basic and diluted loss per common share: | $ |
(0.10 |
) |
$ |
(0.15 |
) |
|
| Basic and diluted weighted average common shares outstanding |
|
61,869 |
|
|
59,650 |
|
|
| See Notes to Consolidated Financial Statements in Part II Item 8 of ChromaDex's Annual Report on Form 10-K to be filed with Securities and Exchange Commission. | |||||||
| ChromaDex Corporation and Subsidiaries | |||||||
| Consolidated Statements of Operations | |||||||
| Years Ended December 31, 2020 and December 31, 2019 | |||||||
| (In thousands, except per share data) | |||||||
|
2020 |
|
|
2019 |
|
||
| Sales, net | $ |
59,257 |
|
$ |
46,291 |
|
|
| Cost of sales |
|
23,983 |
|
|
20,522 |
|
|
| Gross profit |
|
35,274 |
|
|
25,769 |
|
|
| Operating expenses: | |||||||
| Sales and marketing |
|
20,948 |
|
|
18,216 |
|
|
| Research and development |
|
3,732 |
|
|
4,420 |
|
|
| General and administrative |
|
30,448 |
|
|
34,308 |
|
|
| Other |
|
- |
|
|
125 |
|
|
| Operating expenses |
|
55,128 |
|
|
57,069 |
|
|
| Operating loss |
|
(19,854 |
) |
|
(31,300 |
) |
|
| Nonoperating expense: | |||||||
| Interest expense, net |
|
(71 |
) |
|
(847 |
) |
|
| Nonoperating expenses |
|
(71 |
) |
|
(847 |
) |
|
| Net loss |
|
(19,925 |
) |
|
(32,147 |
) |
|
| Basic and diluted loss per common share: | $ |
(0.33 |
) |
$ |
(0.56 |
) |
|
| Basic and diluted weighted average common shares outstanding |
|
61,067 |
|
|
57,056 |
|
|
| See Notes to Consolidated Financial Statements in Part II Item 8 of ChromaDex's Annual Report on Form 10-K to be filed with Securities and Exchange Commission. | |||||||
| ChromaDex Corporation and Subsidiaries | |||||||
| Consolidated Balance Sheets | |||||||
| December 31, 2020 and December 31, 2019 | |||||||
| (In thousands, except per share data) | |||||||
| Dec. 31, 2020 | Dec. 31, 2019 | ||||||
| Assets | |||||||
| Current Assets | |||||||
| Cash, including restricted cash of |
$ |
16,697 |
|
$ |
18,812 |
|
|
| Trade receivables, net of allowances of |
|||||||
| Receivables from Related Party: |
|
2,694 |
|
|
2,175 |
|
|
| Inventories |
|
11,683 |
|
|
11,535 |
|
|
| Prepaid expenses and other assets |
|
1,145 |
|
|
996 |
|
|
| Total current assets |
|
32,219 |
|
|
33,518 |
|
|
| Leasehold Improvements and Equipment, net |
|
3,206 |
|
|
3,765 |
|
|
| Intangible Assets, net |
|
1,082 |
|
|
1,311 |
|
|
| Right of Use Assets |
|
1,226 |
|
|
891 |
|
|
| Other Long-term Assets |
|
625 |
|
|
762 |
|
|
| Total assets | $ |
38,358 |
|
$ |
40,247 |
|
|
| Liabilities and Stockholders' Equity | |||||||
| Current Liabilities | |||||||
| Accounts payable | $ |
9,445 |
|
$ |
9,626 |
|
|
| Accrued expenses |
|
6,133 |
|
|
4,415 |
|
|
| Current maturities of operating lease obligations |
|
589 |
|
|
595 |
|
|
| Current maturities of finance lease obligations |
|
31 |
|
|
258 |
|
|
| Customer deposits |
|
278 |
|
|
169 |
|
|
| Total current liabilities |
|
16,476 |
|
|
15,063 |
|
|
| Deferred Revenue |
|
4,441 |
|
|
3,873 |
|
|
| Operating Lease Obligations, Less Current Maturities |
|
997 |
|
|
848 |
|
|
| Finance Lease Obligations, Less Current Maturities |
|
20 |
|
|
18 |
|
|
| Total liabilities |
|
21,934 |
|
|
19,802 |
|
|
| Commitments and Contingencies | |||||||
| Stockholders' Equity | |||||||
{
"@context": "https://schema.org",
"@type": "FAQPage",
"name": "ChromaDex Corporation Reports 2020 Financial Results FAQs",
"mainEntity": [
{
"@type": "Question",
"name": "What were the Q4 2020 earnings for ChromaDex (CDXC)?",
"acceptedAnswer": {
"@type": "Answer",
"text": "ChromaDex reported Q4 2020 net sales of $15.4 million, an 18% increase from the previous year, with a net loss of $6.1 million."
}
},
{
"@type": "Question",
"name": "How did ChromaDex perform in FY 2020?",
"acceptedAnswer": {
"@type": "Answer",
"text": "For FY 2020, ChromaDex achieved net sales of $59.3 million, up 28% from the prior year, but reported a net loss of $19.9 million."
}
},
{
"@type": "Question",
"name": "What is the outlook for ChromaDex (CDXC) in 2021?",
"acceptedAnswer": {
"@type": "Answer",
"text": "ChromaDex expects continued revenue growth and gross margin improvement, aiming for slightly better than 60% margins in 2021."
}
},
{
"@type": "Question",
"name": "What are the latest developments in ChromaDex's clinical research?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Recent studies suggest that nicotinamide riboside may support human health, including improvements in liver health and recovery from COVID-19."
}
}
]
}
FAQ
What were the Q4 2020 earnings for ChromaDex (CDXC)?
ChromaDex reported Q4 2020 net sales of $15.4 million, an 18% increase from the previous year, with a net loss of $6.1 million.
How did ChromaDex perform in FY 2020?
For FY 2020, ChromaDex achieved net sales of $59.3 million, up 28% from the prior year, but reported a net loss of $19.9 million.
What is the outlook for ChromaDex (CDXC) in 2021?
ChromaDex expects continued revenue growth and gross margin improvement, aiming for slightly better than 60% margins in 2021.
What are the latest developments in ChromaDex's clinical research?
Recent studies suggest that nicotinamide riboside may support human health, including improvements in liver health and recovery from COVID-19.
ChromaDex Corporation
NASDAQ:CDXCCDXC RankingsCDXC Latest NewsCDXC Stock Data
576.36M
49.35M
35.39%
23.87%
3.41%
Packaged Foods
Medicinal Chemicals & Botanical Products
United States of America
LOS ANGELES
| |||||||